test
September 21st 2023
In the first article of a 2-part series, Jack Khouri, MD, discussed the challenges that come with the toxicity profile of selinexor and how physicians can manage these adverse events.
September 19th 2023
September 15th 2023
September 8th 2023
Infection Prevention and Management in Patients Receiving BMCA-Directed Bispecific
February 23rd 2023Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.
Watch
FDA Grants Priority Review to BLA of Elranatamab for R/R Multiple Myeloma
February 22nd 2023Results from cohort A of the MagnetisMM–3 trial of erlanatamab for patients with relapsed/refractory multiple myeloma have led the FDA to grant priority review to a biologics license application for the agent in this patient population.
Read More
Ide-Cel Induces PFS Benefit in Triple-Class-Exposed R/R Multiple Myeloma
February 19th 2023A second interim analysis of the phase 3 Karmma-3 trial demonstrated significantly improved progression-free survival and overall response rates, compared with standard regimens, in patients with triple-class-exposed relapsed/refractory multiple myeloma.
Read More
Chronic Opioid Use After ASCT May Worsen OS in Multiple Myeloma
February 18th 2023A single-center, retrospective study demonstrated high rates of chronic opioid use after autologous stem cell transplantation in patients with multiple myeloma, also leading to inferior overall survival at 6 months of follow-up.
Read More
Roundtable Roundup: Previously Untreated Multiple Myeloma
February 8th 2023In separate live, virtual events, David Dingli, MD, PhD, and Douglas W. Sborov, MD, MS, discussed with participants how they would treat a patient with multiple myeloma in accordance with the available therapeutic regimens.
Read More
Real-World Data Shows Wider Reach for Ide-Cel in RRMM
February 5th 2023After the results of the phase 2 KarMMa trial showed that idecabtagene vicleucel is a new standard of care in relapsed/refractory multiple myeloma, a real-world analysis continues to show the CAR T-cell therapy could have a wider reach.
Read More
Supportive Care for Maintenance in Transplant-Ineligible Multiple Myeloma
February 3rd 2023During a Targeted Oncology case-based roundtable event, Amandeep Godara, MD, discussed the use of maintenance therapy for patients with multiple myeloma. This is the second of 2 articles based on this event.
Read More
Teclistamab Combination Shows Higher Response Rate in Multiple Myeloma
January 27th 2023Emma Searle, PhD, discusses results of the MajestTEC-2 trial combining teclistamab with daratumumab and lenalidomide for patients with multiple myeloma presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Watch